The STD Treatment (Tx) Guidelines mobile app serves as a quick reference guide for doctors and related parties on the identification of and treatment for sexually transmitted diseases (STDs).
SOGC issues Guidelines for the Management of a Pregnant Trauma Patient
SAN BRUNO, CA – June 8, 2015 –Cord Blood Registry® (CBR®), the world’s largest newborn stem cell company, today announced the launch of CBR’s Family Health Registry, a unique registry designed to offer insight into common diseases and conditions affecting families and to bring patients, healthcare professionals and researchers together to expedite and facilitate research related to the discovery of stem cell treatments and potential cures.
The registry serves as an extension to CBR’s Newborn Possibilities Program®, which uses health history screening to identify families who may benefit from cord blood banking and offers free newborn stem cell processing and storage for five years to families with a qualifying medical need. To date, the Newborn Possibilities Program has enrolled more than 6,000 families, storing newborn stem cells for at–risk individuals, releasing more than 70 units for therapeutic use, and connecting patients to FDA–approved autologous cord blood clinical trials.
Profiled health data from family respondents is already yielding valuable information. For example, based on recent survey data, although CBR’s clients are relatively young, a surprisingly high number of families
(approximately 1 in 7) have at least one indicated condition that might benefit from stem cell transplantation and/or potentially from the use of autologous or related allogeneic stem cells in regenerative medicine therapies.
“The combination of individual medical and familial information in an accessible database will empower families interested in preventing illness or reducing risk of disease. It will also help researchers develop insights that may improve outcomes and uses of novel technologies including those using stem cells,” said Paul Billings, MD, PhD, chief medical officer of Omicia, and former founder of CBR.
The most common transplant indications reported among first-degree family members were:
- Non-Hodgkin’s Lymphoma (18.9 percent)
- Hodgkin’s Lymphoma (17.7 percent)
- Acute Lymphoblastic Leukemia (16.2 percent)
- Sarcoma (8.1 percent)
- Acute Myelogenous Leukemia (6.5 percent)
- Sickle Cell Disease (5.7 percent)
The most common regenerative indications among children with stored umbilical cord blood were:
- Autism/Autism Spectrum Disorder/Apraxia (37.2 percent)
- Other Developmental Delay (26.5 percent)
- Congenital Heart Defect (15.8 percent)
- Childhood Hearing Loss (8.2 percent)
- Type I Diabetes (5.3 percent)
- Cerebral Palsy (4.9 percent)
Current trials in the U.S. are studying regenerative uses of umbilical cord blood stem cells for a wide variety of conditions including:
- Cerebral Palsy – Approximately 8,000 to 10,000 babies born in the U.S. each year will develop cerebral palsy (Source: CerebralPalsy.org)
- Ischemic/Hypoxic Brain Injury – Approximately 20 out of every 1,000 full term births and 60 percent of all premature births in the U.S. are affected by Ischemic/Hypoxic Brain Injury (Source:Cerebralpalsy.org)
- Autism – Approximately 58,000 children are diagnosed with autism each year in the U.S. (Source: CDC)
- Acquired Hearing Loss – Approximately 12,000 babies born each year in the U.S. have hearing loss (Source: Boston Children’s Hospital/NIH)
- Hypoplastic Left Heart Syndrome – Over 900 babies in the U.S. each year are born with Hypoplastic Left Heart Syndrome (Source: CDC)
Tel: (415) 318-4262
Cord Blood Registry
Tel: (650) 922-6603
Study finds vaginal progesterone therapy in twin pregnancies with a CL ≤2.5 cm associated with an increased risk of preterm delivery.
This review clearly identifies the need for more evidence, especially in identifying the types and degrees of anaemia likely to have significant impact on the reliability of HbA1c.
The effect of anaemia and abnormalities of erythrocyte indices on HbA1c analysis: a systematic review
Emma English et al.
The World Health Organization recommends RBC folate concentrations should be >400 ng/mL (906 nmol/L) in women of reproductive age to achieve the greatest reduction of NTDs (strong recommendation, low-quality evidence†).
Review supports initiating magnesium sulfate prophylaxis to all women with mild pre eclampsia.
SMFM has provided guidelines and consultation on use of cfDNA, including a joint Committee Opinion with the American College of Obstetricians and Gynecologists (ACOG), a rapid response statement following a high profile article in the Boston Globe, and a recent SMFM Consult Series document published in AJOG